Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: A multicenter portability study

Annals of Clinical and Laboratory Science

Volumn 30, Issue 1, 2000, Pages 41-48

  Persons, Diane L ^a,g   Bui, Marilyn M ^b   Lowery, Mary C ^c,h   Mark, Hon Fong L ^d   Yung, Jar Fee ^e   Birkmeier, Jill M ^f   Wong, Edith Y ⁱ   Yang, Su Jau ^f   Masood, Shahla ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^c Penrose Hospital   (United States)

^d BROWN UNIVERSITY   (United States)

^e MERCY HOSPITAL AND MEDICAL CENTER   (United States)

^f Vysis   (United States)

^g UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^h LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

ⁱ NONE

Author keywords

Breast cancer; DNA probe; ErbB 2; FISH; Gene amplification; HER 2 neu

Indexed keywords

TRASTUZUMAB;

ANALYTIC METHOD; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MULTICENTER STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; CELL NUCLEUS; CYCLOPHOSPHAMIDE; DNA, NEOPLASM; DOUBLE-BLIND METHOD; DOXORUBICIN; FEMALE; FLUOROURACIL; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS;

EID: 0033964715     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. r tumour antigen. Nature 1984; 312:513-516.
2. Slamon DJ, Clark GM, Wong SG et al.. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182.
3. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712.
4. Allred DC, Clark GM, Tandon AK et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10:599-605.
5. Allred DC, Clark GM, Molina R et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Human Pathol 1992; 23:974-979.
6. Murphy DS, Hoare SF, Going JJ et al. Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. J Natl Cancer Inst 1995; 87:1694-1704.
7. Borg A, Baldetorp B, Ferno M et al. erbB2 amplification in breast cancer with a high rate of proliferation. Oncogene 1991; 6:137-143.
8. Ciocca DR, Fujimura FK, Tandon AK, et al. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 1992; 84:1279-1282.
9. Keshgegian AA. ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors. Breast Cancer Res and Treat 1995; 35:201-220.
10. Gullick WJ, Love SB, Wright C et al.. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991; 63:434-438.
11. Borg A, Tandon AK, Sigurdsson H et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; 50:4332-4337.
12. Paterson MC, Dietrich KD, Danyluk J et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991; 51:556-567.
13. Press MF, Pike MC, Chazin V et al. HER-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993; 53:4960-4970.
14. Babiak J, Hugh J, Poppema S. Significance of c-erbB-2 amplification and DNA aneuploidy: analysis of 78 patients with node-negative breast cancer. Cancer 1992; 70:770-776.
15. Press MF, Bernstein L, Thomas PA et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinoma. J Clin Oncol 1997; 15:2894-2904.
16. Andrulis IL, Bull SB, Blackstein ME et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 1998; 16:1340-1349.
17. Muss HB, Thor AD, Berry DA et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330:1260-1266.
18. Thor AD, Berry DA, Budman DR et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90:1346-1360.
19. Paik S, Bryant J, Park C et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90:1361-1370.
20. Wright C, Nicholson S, Angus B et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65:118-121.
21. Carlomagno C, Perrone F, Gallo, C et al.. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14:2702-2708.
22. Bianco AR, De Laurentiis M, Carlomagno C, et al. 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: evidence of interaction between c-erbB2 expression and tamoxifen efficacy. Proceedings of ASCO 1998; 17:Abstract 373:97a.
23. Kallioniemi O, Kallioniemi A, Kurisu W et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci 1992; 89:5321-5325.
24. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996; 13:63-72.
25. Persons DL, Borelli BS, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 1997; 10:720-727.
26. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54:2771-2776.
27. Masood S, Bui MM, Yung J-F et al. Reproducibility of LSI Her-2/neu SpectrumOrange and CEP 17 SpectrumGreen dual color deoxyribonucleic acid probe kit. Ann Clin Lab Sci 1998; 28:215-223.